In this paper, we show that, surprisingly, the primary target of IAP antagonists is cIAP1 and that removal of cIAP1 through genetic deletion or IAC application (1) activates NF-κB signaling that …

Here, we have shown that interfering with IAP function, either through knockdown of IAPs or use of a small molecule IAP antagonist (BV6), can influence TNF-induced production of a range of …

Jan 16, 2017 · In this study, we examined a selection of monovalent and bivalent IAP antagonists and found that specific bivalent IAP antagonists inhibit the TNF-mediated NF- κ B signal …

Nov 5, 2010 · Here, we show that cells depleted of the IAPs by treatment with the IAP antagonist BV6 are greatly sensitized to tumor necrosis factor (TNF)-induced necrosis, but not to necrotic …

Sep 9, 2018 · In addition, the treatment with IAP antagonists can induce TNF-α production via the nuclear factor κB (NF-κB) pathway, leading to collapse of the tumor vasculature and thereby …

The cIAPs ubiquitinate RIPK1 at the TNF receptor (TNFR1) upon TNF-α engagement and promote the formation of a signaling complex (involving the recruitment of another ubiquitin …

Nov 16, 2007 · Collectively, IAP antagonism induces activation of both the canonical and noncanonical NF-κB pathways, irrespective of the presence of a TNF-blocking reagent. …

Initially characterized as inhibitors of apoptosis, the ubiquitin ligase activity of IAP proteins is critical for modulating various signaling pathways (e.g., NF-κB, MAPK) and cellular fate. …

In sensitive tumor lines, IAP antagonist induced NF-kB-stimulated pro-duction of TNFa that killed cells in an autocrine fashion. Inhibition of NF-kB reduced TNFa pro-duction, and blocking NF …

Nov 16, 2007 · In this paper, we show that, surprisingly, the primary target of IAP antagonists is cIAP1 and that removal of cIAP1 through genetic deletion or IAC application (1) activates NF …